Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Economics: Cardiologist allegedly created & sold ransomware tools | Medtronic, GE Healthcare join forces
Tuesday, June 14, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Economics

Cardiologist allegedly created and sold ransomware tools to hackers

One of the cardiologist's creations, "Thanos," allowed his clients to develop their own ransomware software and rent it out to other criminals. 

READ MORE >
Cybersecurity
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist allegedly created and sold ransomware tools to hackers

Share on Twitter Share on Facebook Share on Linkedin
Cybersecurity
One of the cardiologist's creations, "Thanos," allowed his clients to develop their own ransomware software and rent it out to other criminals. 
READ MORE >

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

READ MORE >
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

Share on Twitter Share on Facebook Share on Linkedin
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.
READ MORE >

VIDEO: Creating an integrated heart team program in central Texas

Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.

READ MORE >
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Creating an integrated heart team program in central Texas

Share on Twitter Share on Facebook Share on Linkedin
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.
READ MORE >

Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

READ MORE >
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
Share on Twitter Share on Facebook Share on Linkedin

Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Share on Twitter Share on Facebook Share on Linkedin
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 
READ MORE >

Medtronic, GE Healthcare join forces on new-look continuous monitoring solution

The collaboration is aimed at improving patient outcomes after cardiac surgeries and other procedures. 

READ MORE >
Medtronic and GE Healthcare have received FDA clearance and CE mark approval for a new collaboration designed to improve patient monitoring. The combined solution involves the integration of Medtronic’s INVOS regional oximetry and Microstream capnography technologies into GE Healthcare’s CARESCAPE precision monitoring platform.
Share on Twitter Share on Facebook Share on Linkedin

Medtronic, GE Healthcare join forces on new-look continuous monitoring solution

Share on Twitter Share on Facebook Share on Linkedin
Medtronic and GE Healthcare have received FDA clearance and CE mark approval for a new collaboration designed to improve patient monitoring. The combined solution involves the integration of Medtronic’s INVOS regional oximetry and Microstream capnography technologies into GE Healthcare’s CARESCAPE precision monitoring platform.
The collaboration is aimed at improving patient outcomes after cardiac surgeries and other procedures. 
READ MORE >

Medical device company raises $23M for fully absorbable vessel closure patches

Vivasure Medical will use the funds to advance clinical development and attempt to secure regulatory approval of its vessel closure devices.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Medical device company raises $23M for fully absorbable vessel closure patches

Share on Twitter Share on Facebook Share on Linkedin
Vivasure Medical will use the funds to advance clinical development and attempt to secure regulatory approval of its vessel closure devices.
READ MORE >

LVAD patients spend nearly 1 in 4 days seeking care — is there a more effective way?

The study's authors noted that LVADs consistently lead to strong outcomes, but improvements are still needed to reduce the burden on patients. 

READ MORE >
Treating elderly atrial fibrillation (AFib) patients—even those who are traditionally ineligible for direct oral anticoagulants (DOACs)—with a very low dose of edoxaban is associated with improved outcomes, according to new research published in JAMA Network Open.
Share on Twitter Share on Facebook Share on Linkedin

LVAD patients spend nearly 1 in 4 days seeking care — is there a more effective way?

Share on Twitter Share on Facebook Share on Linkedin
Treating elderly atrial fibrillation (AFib) patients—even those who are traditionally ineligible for direct oral anticoagulants (DOACs)—with a very low dose of edoxaban is associated with improved outcomes, according to new research published in JAMA Network Open.
The study's authors noted that LVADs consistently lead to strong outcomes, but improvements are still needed to reduce the burden on patients. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme